Claims for Patent: 12,257,236

Summary for Patent: 12,257,236

Title:	Oral formulations of metronidazole and methods of treating an infection using same
Abstract:	The present disclosure provides oral pharmaceutical compositions comprising: 1) metronidazole or a pharmaceutically acceptable salt thereof; and magnesium aluminum silicate; or 2) metronidazole or a pharmaceutically acceptable salt thereof; magnesium aluminum silicate; and a flavoring agent. Methods of treating infection utilizing the oral pharmaceutical compositions are also provided.
Inventor(s):	Bernard J. Guarino, Jr., Jamie L. Doran, Zorana Radovic, Kevin Sullivan, Armand Louis Balboni
Assignee:	Appili Therapeutics Inc
Application Number:	US18/072,154
Patent Claims:	1. An oral pharmaceutical liquid suspension comprising a) metronidazole or a pharmaceutically acceptable salt thereof; and b) magnesium aluminum silicate, wherein the magnesium aluminum silicate is a natural product. 2. An oral pharmaceutical liquid suspension comprising a) metronidazole or a pharmaceutically acceptable salt thereof; b) magnesium aluminum silicate; and c) and at least one flavoring agent, wherein the magnesium aluminum silicate is a natural product. 3. The oral pharmaceutical liquid suspension of claim 1, further comprising at least one sweetener. 4. The oral pharmaceutical liquid suspension of claim 1, wherein the metronidazole or a pharmaceutically acceptable salt thereof is present at a concentration of about 250 mg per 5 ml of the oral pharmaceutical liquid suspension. 5. The oral pharmaceutical liquid suspension of claim 1, wherein the metronidazole or a pharmaceutically acceptable salt thereof is metronidazole base. 6. The oral pharmaceutical liquid suspension of claim 1, wherein the magnesium aluminum silicate is magnesium aluminum silicate Type 1C. 7. The oral pharmaceutical liquid suspension of claim 1, wherein the concentration of magnesium aluminum silicate is between 1% and 10% (w/v) of the oral pharmaceutical. 8. The oral pharmaceutical liquid suspension of claim 3, wherein the sweetener is a natural sweetener selected from the group consisting of sucrose, glucose, fructose, stevia, and mixtures thereof. 9. The oral pharmaceutical liquid suspension of claim 3, wherein the sweetener is an artificial sweetener selected from the group consisting of sucralose, sorbitol, saccharin, aspartame, acesulfame potassium, neotame, advantame, and mixtures thereof. 10. The oral pharmaceutical liquid suspension of claim 2, wherein the at least one flavoring agent is selected from the group consisting of natural flavors, artificial flavors, mint, and mixtures thereof. 11. The oral pharmaceutical liquid suspension of claim 10, wherein the natural flavor is a natural fruit flavor selected from the group consisting of cherry, strawberry, raspberry, and mixtures thereof. 12. The oral pharmaceutical liquid suspension of claim 10, wherein the mint is peppermint. 13. The oral pharmaceutical liquid suspension of claim 10, wherein the at least one flavoring agent comprises cherry, strawberry, raspberry, peppermint, or mixtures thereof. 14. The oral pharmaceutical liquid suspension of claim 1, further comprising one or more excipients, wherein the one or more excipients comprises one or more of a preservative, a buffer, a viscosity agent, and a solvent. 15. The oral pharmaceutical liquid suspension of claim 14, wherein the buffer comprises sodium phosphate monobasic or sodium phosphate dibasic. 16. The oral pharmaceutical liquid suspension of claim 14, wherein the solvent comprises one or more of glycerol, alcohol, propylene glycol, or a combination thereof. 17. An oral pharmaceutical liquid suspension comprising: metronidazole, sucrose, glycerin, purified water, magnesium aluminum silicate, microcrystalline cellulose, sucralose, sodium phosphate, one or more preservatives, strawberry flavoring agent and peppermint flavoring agent, wherein the magnesium aluminum silicate is a natural product. 18. A method of treating an infection in a patient, said method comprising the step of administering to the patient an effective amount of an oral pharmaceutical liquid suspension comprising: a) metronidazole or a pharmaceutically acceptable salt thereof and magnesium aluminum silicate; or b) metronidazole or a pharmaceutically acceptable salt thereof; magnesium aluminum silicate; and at least one flavoring agent; wherein the magnesium aluminum silicate is a natural product. 19. The method of claim 18, wherein the infection is a bacterial infection, a fungal infection, a protozoan infection, amebiasis, pelvic inflammatory disease, endocarditis, bacterial vaginosis, dracunculiasis, giardiasis, or trichomoniasis. 20. The method of claim 19, wherein the bacterial infection is caused by one or more of a gram-positive bacterium, a gram-negative bacterium, an aerobic bacterium and an anaerobic bacterium. 21. The method of claim 18, wherein the patient is a geriatric patient or a pediatric patient.